| Literature DB >> 35770262 |
Jin-Uk Choi1, Shin Hwang1, I-Ji Chung1, Sang-Hyun Kang1, Chul-Soo Ahn1, Deok-Bog Moon1, Tae-Yong Ha1, Ki-Hun Kim1, Gi-Won Song1, Dong-Hwan Jung1, Gil-Chun Park1, Young-In Yoon1, Hui-Dong Cho1, Sung-Gyu Lee1.
Abstract
Background: Living donor liver transplantation (LDLT) causes bleeding in recipients during the careful preservation of most perihilar structures during this surgery. This case-control study aimed to analyze the effect of prolonged hepatic inflow occlusion (PHIO) when applied during recipient hepatectomy in LDLT.Entities:
Keywords: Bleeding; Living donor liver transplantation; Portal hypertension; Pringle maneuver
Year: 2020 PMID: 35770262 PMCID: PMC9188952 DOI: 10.4285/kjt.2020.34.1.55
Source DB: PubMed Journal: Korean J Transplant ISSN: 2671-8790
Fig. 1Concept of prolonged hepatic inflow occlusion. (A) Interruption of the main portal flow and hepatic arterial flow in a patient with liver cirrhosis, and portal hypertension does not induce significant splanchnic congestion because of portal bypass through venous collaterals. Adapted from Choi et al. Ann Hepatobiliary Pancreat Surg 2019;23:61-4 [3]. (B) A curved intestinal clamp is attached to the hepatoduodenal ligament for right liver mobilization.
Clinical profiles of the PHIO study group and two control groups
| Variable | PHIO study group (A) | Low-MELD score control group (B) | High-MELD score control group (C) | P-value (A vs. B) | P-value (A vs. C) |
|---|---|---|---|---|---|
| No. of cases | 20 | 40 | 40 | NA | NA |
| Age (yr) | 49.0±9.2 | 51.7±6.6 | 52.8±7.5 | 0.32 | 0.13 |
| Sex (male:female) | 14:6 | 32:8 | 28:11 | 0.39 | 0.89 |
| MELD score | 29.2±2.3 | 17.8±1.7 | 30.7±2.8 | <0.001 | 0.24 |
| Primary liver disease | 0.58 | 0.86 | |||
| Hepatitis B virus-associated cirrhosis | 10 | 23 | 19 | ||
| Hepatitis C virus-associated cirrhosis | 1 | 7 | 3 | ||
| Alcoholic liver disease | 4 | 5 | 6 | ||
| Others | 4 | 5 | 12 | ||
| ABO blood group incompatibility | 1 | 6 | 3 | 0.69 | 0.79 |
| Concurrent hepatocellular carcinoma | 5 | 14 | 3 | 0.43 | 0.060 |
| Laboratory profiles | |||||
| Hemoglobin (g/dL) | 9.3±1.5 | 10.5±1.7 | 9.8±1.9 | 0.12 | 0.54 |
| Platelet (×103 µ/L) | 64.2±52.6 | 61.7±57.9 | 60.6±41.1 | 0.18 | 0.092 |
| Albumin (g/dL) | 3.2±0.6 | 3.0±0.9 | 3.0±0.6 | 0.24 | 0.38 |
| Total bilirubin (mg/dL) | 22.4±11.5 | 6.0±4.3 | 24.0±11.4 | <0.001 | 0.13 |
| Creatinine (mg/dL) | 1.75±2.48 | 0.74±0.25 | 1.57±2.01 | <0.001 | 0.095 |
| Prothrombin time (INR) | 2.94±2.49 | 2.18±3.36 | 2.84±1.34 | <0.001 | 0.23 |
| Pretransplant renal replacement therapy | 2 | 0 | 4 | NA | 0.99 |
| Graft type | 0.21 | 0.74 | |||
| Modified right liver graft | 18 | 39 | 37 | ||
| Extended right liver graft | 2 | 1 | 2 | ||
| Extended left liver graft | 0 | 0 | 1 | ||
| Graft-recipient weight ratio | 1.12±0.18 | 1.08±0.21 | 1.14±0.17 | 0.27 | 0.46 |
Values are presented as mean±standard deviation.
PHIO, prolonged hepatic inflow occlusion; MELD, Model for End-Stage Liver Disease; NA, not applicable.
Fig. 2Comparison of the total liver dissection duration in the prolonged hepatic inflow occlusion (PHIO) study group and two Model for End-Stage Liver Disease (MELD) score control groups.
Fig. 3Comparison of amount of blood loss during liver dissection in the prolonged hepatic inflow occlusion (PHIO) study group and two Model for End-Stage Liver Disease (MELD) score control groups.
| HIGHLIGHTS |
|---|
|
Prolonged hepatic inflow occlusion is a simple effective method to reduce intraoperative bleeding during hepatic mobilization and dissection during living donor liver transplantation operation requiring difficult dissection. |